Live Birth Outcomes for PCOS Patients Under the Follicular-Phase Long-Acting GnRH Agonist Protocol or Antagonist Protocol – A Retrospective Chinese Cohort

References

• Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. Int J Adolesc Med Health. 2021;34(2):1–9. doi:10.1515/ijamh-2021-0073
   PubMedGoogle Scholar
• Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668–680. doi:10.1016/S2213-8587(22)00163-2
   PubMed Web of Science ®Google Scholar
• Orvieto R, Meltcer S, Homburg R, Nahum R, Rabinson J, Ashkenazi J. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization? Fertil Steril. 2009;91(4 Suppl):1466–1468. doi:10.1016/j.fertnstert.2008.07.1711
   PubMed Web of Science ®Google Scholar
• Wang N, Zhu Q, Ma M, et al. Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial. BMJ open. 2020;10(12):e038153. doi:10.1136/bmjopen-2020-038153
   PubMed Web of Science ®Google Scholar
• Wang D, Chu T, Yu T, Zhai J. Is early-follicular long-acting GnRH agonist protocol an alternative for patients with polycystic ovary syndrome undergoing in vitro fertilization? Reprod Biol Endocrinol. 2022;20(1):137. doi:10.1186/s12958-022-01007-z
   PubMed Web of Science ®Google Scholar
• Kadoura S, Alhalabi M, Nattouf AH. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis. Sci Rep. 2022;12(1):4456. doi:10.1038/s41598-022-08400-z
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao W, Han Y, et al. The follicular-phase depot GnRH agonist protocol results in a higher live birth rate without discernible differences in luteal function and child health versus the daily mid-luteal GnRH agonist protocol: a single-centre, retrospective, propensity score matched cohort study. Reprod Biol Endocrinol. 2022;20(1):140.
   PubMed Web of Science ®Google Scholar
• Song J, Wu W, Jiang L, Duan C, Xu J. Effects of different exposure days to gonadotropin-releasing hormone agonist (GnRH-A) on live birth rates in the depot GnRH-A protocol: a retrospective analysis of 7007 Cycles. Med Sci Monit. 2021;27:e929854. doi:10.12659/MSM.929854
   PubMed Web of Science ®Google Scholar
• Xia M, Zheng J. Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders. BMC Pregnancy Childbirth. 2021;21(1):372. doi:10.1186/s12884-021-03849-8
   PubMed Web of Science ®Google Scholar
• Li R, Gong F, Chen H, Wang Q, Qiao J. Correlation of LH level and steroid concentrations in GnRH antagonist protocol: a sub-analysis of Ganirelix Phase III study of China. J Gynecol Obstet Hum. 2022;51(5):102363. doi:10.1016/j.jogoh.2022.102363
   Web of Science ®Google Scholar
• Yang R, Guan Y, Perrot V, Ma J, Li R. Comparison of the long-acting GnRH agonist follicular protocol with the GnRH antagonist protocol in women undergoing in vitro fertilization: a systematic review and meta-analysis. Adv Ther. 2021;38(5):2027–2037. doi:10.1007/s12325-020-01612-7
   PubMed Web of Science ®Google Scholar
• Costello MF, Garad RM, Hart R, et al. A review of second- and third-line infertility treatments and supporting evidence in women with polycystic ovary syndrome. Med Sci. 2019;7(7). doi:10.3390/medsci7070075
   Google Scholar
• Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. doi:10.1016/j.fertnstert.2016.05.003
   PubMed Web of Science ®Google Scholar
• Zegers-Hochschild F, Adamson GD, Dyer S, et al. The international glossary on infertility and fertility care, 2017. Fertil Steril. 2017;108(3):393–406. doi:10.1016/j.fertnstert.2017.06.005
   PubMed Web of Science ®Google Scholar
• Duffy JMN, Bhattacharya S, Bhattacharya S, et al. Standardizing definitions and reporting guidelines for the infertility core outcome set: an international consensus development study. Fertil Steril. 2021;115(1):201–212. doi:10.1016/j.fertnstert.2020.11.013
   PubMed Web of Science ®Google Scholar
• Zegers-Hochschild F, Adamson GD, de Mouzon J, et al. International committee for monitoring assisted reproductive technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril. 2009;92(5):1520–1524. doi:10.1016/j.fertnstert.2009.09.009
   PubMed Web of Science ®Google Scholar
• Tandulwadkar S, Gupta S, Singh A, Mishra S, Singhania S. Medroxyprogesterone acetate versus gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles. JBRA Assist Reprod. 2022. doi:10.5935/1518-0557.20220006
   Web of Science ®Google Scholar
• Drakopoulos P, Racca A, Errázuriz J, et al. The role of progesterone elevation in IVF. Reprod Biol. 2019;19(1):1–5. doi:10.1016/j.repbio.2019.02.003
   PubMed Web of Science ®Google Scholar
• Li G, Wu Y, Niu W, et al. Analysis of the number of euploid embryos in preimplantation genetic testing cycles with early-follicular phase long-acting gonadotropin-releasing hormone agonist long protocol. Front Endocrinol. 2020;11:424. doi:10.3389/fendo.2020.00424
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang D, Sun Z, Deng C, Yu Q, Zhen J. The effect of a transient premature luteinizing hormone surge without elevated serum progesterone on in vitro fertilization outcomes in a gonadotropin-releasing hormone antagonist flexible protocol. Gynecol Endocrinol. 2020;36(6):550–553. doi:10.1080/09513590.2019.1683730
   PubMed Web of Science ®Google Scholar
• Song J, Duan C, Cai W, et al. Comparison of GnRH-A prolonged protocol and short GnRH-A long protocol in patients with thin endometrium for assisted reproduction: a retrospective cohort study. Drug Des Devel Ther. 2020;14:3673–3682. doi:10.2147/DDDT.S270519
   PubMed Web of Science ®Google Scholar
• Li L, Liu L, Kou Z, Huo M, An J, Zhang X. GnRH agonist treatment regulates IL-6 and IL-11 expression in endometrial stromal cells for patients with HRT regiment in frozen embryo transfer cycles. Reprod Biol. 2022;22(2):100608. doi:10.1016/j.repbio.2022.100608
   PubMed Web of Science ®Google Scholar
• Xu B, Geerts D, Hu S, et al. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study. Hum Reprod. 2020;35(6):1306–1318. doi:10.1093/humrep/deaa086
   PubMed Web of Science ®Google Scholar
• Lambalk C, Banga F, Huirne J, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560–579. doi:10.1093/humupd/dmx017
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Youssef M, Ayeleke R, Brown J, Lam W, F B. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750. doi:10.1002/14651858.CD001750.pub4
   PubMedGoogle Scholar
• Kuroda K, Nagai S, Ikemoto Y, et al. Incidences and risk factors of moderate-to-severe ovarian hyperstimulation syndrome and severe hemoperitoneum in 1,435,108 oocyte retrievals. Reprod Biomed Online. 2021;42(1):125–132. doi:10.1016/j.rbmo.2020.09.001
   PubMed Web of Science ®Google Scholar
• Wang B, Wang J, Liu Y, et al. sRAGE downregulates the VEGF expression in OHSS ovarian granulosa cells. Gynecol Endocrinol. 2021;37(9):836–840. doi:10.1080/09513590.2021.1942453
   PubMed Web of Science ®Google Scholar
• Hortu I, Karadadas E, Ozceltik G, et al. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Arch Gynecol Obstet. 2021;303(4):1099–1108. doi:10.1007/s00404-020-05855-1
   PubMed Web of Science ®Google Scholar
• Deepika K, Suvarna R, Sumi M, et al. HCG trigger versus GnRH agonist trigger in PCOS patients undergoing IVF cycles: frozen embryo transfer outcomes. JBRA Assist Reprod. 2021;25(1):48–58. doi:10.5935/1518-0557.20200028
   PubMed Web of Science ®Google Scholar
• Shen X, Yang Q, Li L, Lu W. Clinical pregnancy and incidence of ovarian hyperstimulation syndrome in high ovarian responders receiving different doses of hCG supplementation in a GnRH-Agonist trigger protocol. Evid Based Complement Alternat Med. 2021;2021:2180933. doi:10.1155/2021/2180933
   PubMed Web of Science ®Google Scholar
• Mizrachi Y, Horowitz E, Farhi J, Raziel A, AJHru W. Ovarian stimulation for freeze-all IVF cycles: a systematic review. Hum Reprod Update. 2020;26(1):118–135. doi:10.1093/humupd/dmz037
   PubMed Web of Science ®Google Scholar
• Shi Y, Sun Y, Hao C, et al. Transfer of Fresh versus frozen embryos in ovulatory women. N Engl J Med. 2018;378(2):126–136. doi:10.1056/NEJMoa1705334
   PubMed Web of Science ®Google Scholar